All of these, except the Johnson & Johnson vaccine, involve a two-dose regimen, and many of them require storage at cold or ultracold temperatures. The current COVID-19 vaccines include mRNA vaccines, such as the Pfizer-BioNTech and Moderna vaccines, and adenovirus vaccines, such as the Oxford-AstraZeneca and Johnson & Johnson vaccines. The finite global manufacturing capacity and the lack of the necessary cold storage infrastructure in low income countries are some of the major challenges impeding the global supply and availability of vaccines.
Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment. With the successful vaccination of a substantial proportion of the population in wealthier countries, the supply and distribution of vaccines to middle and low income nations are improving.
However, despite the increase in the supply of the vaccines that provide a high degree of protection against COVID-19, the vaccines do have limitations. This inequitable distribution is, at least partly, due to the limited supply of vaccines and the stockpiling of vaccines by rich nations.
Lead author of the study, Dr. Luk Vandenberghe, associate professor at Harvard University and director of the Grousbeck Gene Therapy Center in Boston, MA, told Medical News Today: “COVID-19 is a continued global health concern for which a number of highly effective vaccines are available to mitigate the pandemic. The data on our experimental vaccine shows that it has the potential to address two of the remaining concerns that prevent effective management of the situation.” Authors of a recent study, which appears in the journal Cell Host & Microbe, found that a single dose of a vaccine candidate AAVCOVID-1 (AC1) elicited an immune response against SARS-CoV-2 for at least 11 months in macaques. The vaccine candidate was also stable at room temperature for 1 month and produced an immune response against current variants of concern.
To address these concerns, a group of researchers is developing a vaccine candidate using an AAV as a vector. This, along with the emergence of new SARS-CoV-2 variants and the uncertainty about the duration of protection the currently available vaccines provide, suggests the need for new, durable, and easily deployable vaccines.
The News Highlights
- COVID-19 Experimental Vaccine May Offer Hope for Low-Income Countries
- Check the latest Health news updates and information about health.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week